Karyopharm Therapeutics Inc.
KPTI
$8.38
-$0.17-1.99%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.58% | 13.57% | -11.35% | -9.39% | -9.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.58% | 13.57% | -11.35% | -9.39% | -9.50% |
| Cost of Revenue | -15.83% | -12.76% | -15.05% | -3.80% | -15.25% |
| Gross Profit | 220.46% | 744.11% | 38.64% | -40.24% | 42.54% |
| SG&A Expenses | -16.25% | -3.71% | -8.35% | -7.44% | -11.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.01% | -8.92% | -12.11% | -5.40% | -13.60% |
| Operating Income | 42.96% | 42.09% | 13.28% | 1.49% | 17.26% |
| Income Before Tax | -231.07% | -3.27% | -255.97% | 37.18% | 25.94% |
| Income Tax Expenses | 38.53% | 21.43% | -40.30% | -49.30% | -183.85% |
| Earnings from Continuing Operations | -232.03% | -3.29% | -256.57% | 37.20% | 26.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -232.03% | -3.29% | -256.57% | 37.20% | 26.43% |
| EBIT | 42.96% | 42.09% | 13.28% | 1.49% | 17.26% |
| EBITDA | 42.87% | 42.37% | 13.27% | 1.47% | 17.31% |
| EPS Basic | -55.63% | 0.68% | -291.06% | 32.98% | 32.92% |
| Normalized Basic EPS | 39.46% | 0.69% | -67.13% | 42.90% | 32.47% |
| EPS Diluted | -55.67% | 0.68% | -45.40% | 32.98% | 32.92% |
| Normalized Diluted EPS | 39.46% | 0.69% | -113.22% | 42.90% | 32.47% |
| Average Basic Shares Outstanding | 113.34% | 3.99% | 6.83% | 10.01% | 9.67% |
| Average Diluted Shares Outstanding | 113.34% | 3.99% | -16.27% | 10.01% | 9.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |